This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05456/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05456/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05456/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05456
rdf:type
n3:Drug
n3:description
ETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol and other lipids from cells including those in the arterial wall. LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway. It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis. Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes.
n3:generalReferences
# Martin K, Brownfield D, Karmonik C, Sanford L, Torres L, Insull W, Morrisett J: Short-term tracking of atherosclerosis in operated and unoperated human carotid arteries by high resolution magnetic resonance imaging. World J Surg. 2007 Apr;31(4):723-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17354027 # Doggrell SA: ETC-588 (Pfizer). Curr Opin Investig Drugs. 2004 Sep;5(9):993-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15503656
n3:group
investigational
n3:indication
Investigated for use/treatment in atherosclerosis, coronary artery disease, and vascular diseases.
owl:sameAs
n6:DB05456
dcterms:title
ETC-588
adms:identifier
n8:4952476 n10:DB05456 n11:6449792
n3:mechanismOfAction
ETC-588 is a phospholipid bilayer that can sequester cholesterol. Once the HDL particle, which is small enough to enter the arterial wall, pulls the cholesterol out of the plaque, it readily hands the cholesterol over to the LUV. The LUV then transports the cholesterol to the liver for processing.
n3:IUPAC-Name
n4:271B4414-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B441A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4419-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4416-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4417-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4418-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4412-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4410-363D-11E5-9242-09173F13E4C5 n4:271B4413-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4411-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4420-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4421-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B441B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B441C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B441E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B441D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B441F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4426-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4428-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4429-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4425-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4424-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4427-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4415-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4422-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4423-363D-11E5-9242-09173F13E4C5